Terms: = Pancreatic cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Clinical Outcome
3 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Improved Risk Stratification by Circulating Tumor Cell Counts in pancreatic cancer.
Effenberger KE; Schroeder C; Hanssen A; Wolter S; Eulenburg C; Tachezy M; Gebauer F; Izbicki JR; Pantel K; Bockhorn M
Clin Cancer Res; 2018 Jun; 24(12):2844-2850. PubMed ID: 29559560
[No Abstract] [Full Text] [Related]
3. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract] [Full Text] [Related]
